Stockscreener 앱 받기
4.92
2.19%
-0.11
전일 마감가:
$5.03
열려 있는:
$5.09
하루 거래량:
214.34K
Relative Volume:
1.33
시가총액:
$115.41M
수익:
$7.94M
순이익/손실:
$-21.13M
주가수익비율:
-4.548
EPS:
-1.0818
순현금흐름:
$-16.17M
1주 성능:
+6.03%
1개월 성능:
+0.00%
6개월 성능:
-7.17%
1년 성능:
-10.71%
1일 변동 폭
$4.81
$5.1297
1주일 범위
$4.57
$5.21
52주 변동 폭
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.92 | 115.41M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - BioSpace
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Institutional Confidence - TradingKey
Coya Therapeutics Inc (COYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - Business Wire
COYA Maintains Buy Rating by Chardan Capital -- Price Target at $14 - GuruFocus
Coya Therapeutics (COYA) Gains 2.16% as Stock Nears Key Resistance ZoneDip Buy Trade - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Coya Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact - Yahoo Finance
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase - BioSpace
COYA Q1 2026 Earnings: EPS Surprises Wall Street with Narrower Loss, Stock DeclinesAnnual Financial Report - newsline.com
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Roth MKM Initiates Coya Therapeutics(COYA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Roth/MKM initiates Coya Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Roth/MKM initiates Coya Therapeutics stock with buy rating - Investing.com
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Coya Therapeutics (COYA) Surges 1.87% as Shares Approach Resistance ZoneStock Picks - newsline.com
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - BioSpace
COYA Q1 2026 Earnings: EPS Beat Provides Silver Lining as Revenue Remains AbsentEarnings Expansion Phase - The Legal Advocate
COYA Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances PipelineQuarterly Earnings - The Legal Advocate
COYA Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Rises on Efficiency GainsGuidance vs Actual - The Legal Advocate
COYA | Coya Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Coya Therapeutics secures FDA fast track status for COYA 302 - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Lake Street Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
8-K: Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Chardan Capital Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
FDA puts injection therapy COYA 302 on fast track for treating ALS - ALS News Today
[ARS] Coya Therapeutics, Inc. SEC Filing - Stock Titan
Coya Therapeutics (COYA) 2026 proxy outlines director elections and auditor ratification - Stock Titan
Coya Therapeutics 1Q Research and Development Expenses $4.1 M >COYA - Moomoo
FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential - Streetwise Reports
Coya Therapeutics Announces $30 Million At-the-Market Offering Agreement with Leerink Partners - Minichart
Coya Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coya Therapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Market Risks, and Legal Disclosures - Minichart
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of - pharmiweb.com
Coya Therapeutics Establishes $30 Million ATM Equity Program - TipRanks
Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million - marketscreener.com
Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million - TradingView
Coya Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Coya Therapeutics Updates Q1 Results, COYA 302 Progress - TipRanks
Coya Therapeutics (COYA) launches $30,000,000 at-the-market stock offering - Stock Titan
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):